Annovis Bio upgraded by Maxim Group with a new price target
$ANVS
Biotechnology: Pharmaceutical Preparations
Health Care
Maxim Group upgraded Annovis Bio from Hold to Buy and set a new price target of $25.00
Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/10/2025 | Buy → Hold | D. Boral Capital | |
10/25/2024 | $25.00 | Hold → Buy | Maxim Group |
12/29/2023 | $36.00 | Buy | Canaccord Genuity |
7/7/2021 | $45.00 → $150.00 | Buy | Maxim Group |
D. Boral Capital downgraded Annovis Bio from Buy to Hold
Maxim Group upgraded Annovis Bio from Hold to Buy and set a new price target of $25.00
Canaccord Genuity initiated coverage of Annovis Bio with a rating of Buy and set a new price target of $36.00